Guildford, UK, 23 August 2006: ReNeuron Group plc (LSE: RENE) today announces that it has sent notice to its Shareholders and Warrant holders convening its 2006 Annual General Meeting (the AGM) and a meeting of its Warrant holders, each meeting to be held on 21 September 2006.
Guildford, UK, 7 March 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will participate in the 2006 BioSquare conference at the International Conference Centre, Geneva, Switzerland on March 8-10. Dr Paul Harper, a Non-executive Director of ReNeuron, will present in the Gene/Cell Therapy section of the conference on March 9 at 15:15pm local time. Dr Harper has been closely involved in the pre-clinical development of ReNeuron’s ReN001 stem cell therapy for stroke, and will give an overview of this and the Company’s other programmes at the conference.
Guildford, UK, 29 June 2006: ReNeuron Group plc (LSE: RENE) today announces that it will be presenting significant new data concerning both its c-mycERTAM stem cell expansion technology and its ReN001 stem cell line for stroke at leading international stem cell and neuroscience conferences.
Guildford, UK: 28 June 2006: ReNeuron Group plc (the “Company“) today announces that it has received commitments in respect of a placing of 5,500,000 new ordinary shares of 10p each credited as fully paid (“Ordinary Shares“) at a price of 13p per share (the “Placing“). Collins Stewart Limited acted as nominated adviser and broker to the Company in connection with the Placing.
Guildford, UK, 26 June 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will report its preliminary results for the year ending 31 March 2006 on Wednesday 28 June 2006.
Guildford, UK, 5 June 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it will participate in the European Stem Cells & Regenerative Medicine Congress 2006 at the Jumeirah Carlton Tower Hotel, London on June 5-7.
Guildford, UK, 18 April 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it has entered into a further agreement with StemCells, Inc. (‘StemCells’), a leading US, NASDAQ-quoted adult stem cell development company. The agreement provides for ReNeuron to supply StemCells with cell lines generated using ReNeuron’s proprietary c-mycERTAM human stem cell immortalisation technology, for use in StemCells’ areas of therapeutic focus.
Guildford, UK, 18 April 2006: ReNeuron Group plc (LSE: RENE.L) today announces that it has signed an agreement with Chemicon International, Inc. (‘Chemicon’), a subsidiary of Serologicals Corporation (NASDAQ/NM: SERO), whereby Chemicon will exclusively manufacture and distribute two of ReNeuron’s patented ReNcellTM neural stem cell lines worldwide for research purposes.
Guildford, UK, 5 April 2006: ReNeuron Group plc (AIM: RENE) announces that it proposes to raise up to £8.5 million via a non pre-emptive placing of new ordinary shares and American Depositary Shares (ADSs) (the “Placing”). The Company intends that institutional investors (including US and certain existing institutional shareholders) will participate in the Placing. The proceeds of the Placing will be used to fund the Company’s lead ReN001 programme for stroke as it progresses to the clinic, and also to fund the Company’s other therapeutic programmes based on recently announced progress made.
